Innovation Pharmaceuticals Inc (IPIX)

[Roger 2]

.not "pie in the sky"

https://www.europeanpharmaceuticalreview.com/article/111051/the-biggest-pharma-merger-and-acquisition-deals-of-2019/


https://en.wikipedia.org/wiki/List_of_largest_pharmaceutical_mergers_and_acquisitions
Number 46 on this list, Onyx, sold for $10.4Bil in 2013. Their three successful cancer treatments have current annual sales of around $2.5Bil

Number 7, Shire, had (2018 before sale negotiations) 6 month sales of ~$7.46 Bil, Royalty and other revenue of ~ $0.250Bil. It also had ongoing debt of ~($17.7 Bil.)
http://investors.shire.com/~/media/Files/S/Shire-IR/documents/half-yearly-report-2018.pdf
It had several drugs in pipeline. Sold for $62Bil. in Jan 2019.

Depending on projected sales of IPIX products and the subjective value of a new (and proven if B is successful) treatment genre to an industry winding down proprietary medications I wouldn't be afraid to dream in capital numbers.

Big Pharma apparently has the bucks to meet high investor expectations.